Qualigen Therapeutics (QLGN)
(Delayed Data from NSDQ)
$0.20 USD
+0.01 (3.06%)
Updated Jun 14, 2024 03:57 PM ET
After-Market: $0.20 0.00 (0.50%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Qualigen Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 5 | 6 | 0 | 0 |
Cost Of Goods | 0 | 4 | 4 | 0 | 0 |
Gross Profit | 0 | 1 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 11 | 23 | 24 | 0 | 11 |
Income After Depreciation & Amortization | -11 | -22 | -23 | 0 | -11 |
Non-Operating Income | 0 | 1 | 5 | 0 | 1 |
Interest Expense | 2 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | -21 | -18 | 0 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | -2 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -12 | -21 | -18 | 0 | -10 |
Extras & Discontinued Operations | -1 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -13 | -19 | -18 | 0 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -10 | -22 | -22 | 0 | -11 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -11 | -22 | -23 | 0 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.07 | 3.84 | 2.93 | NA | 0.04 |
Diluted EPS Before Non-Recurring Items | -2.46 | -4.85 | -7.70 | NA | -265.00 |
Diluted Net EPS (GAAP) | -2.65 | -4.85 | -6.10 | NA | -265.00 |
Fiscal Year end for Qualigen Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | -3.23 | 0.00 | 1.63 | 1.61 |
Cost Of Goods | NA | -2.28 | 0.00 | 1.02 | 1.26 |
Gross Profit | NA | -0.95 | 0.00 | 0.61 | 0.34 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.33 | 2.78 | 4.17 | 4.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.28 | -2.78 | -3.56 | -3.69 |
Non-Operating Income | NA | 0.09 | -0.09 | 0.38 | -0.03 |
Interest Expense | NA | 0.24 | 0.37 | 0.38 | 0.54 |
Pretax Income | NA | -1.43 | -3.24 | -3.55 | -4.27 |
Income Taxes | NA | 0.20 | 0.00 | -0.04 | -0.16 |
Minority Interest | NA | 0.00 | -0.04 | -0.04 | -0.26 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.63 | -3.24 | -3.51 | -4.11 |
Extras & Discontinued Operations | NA | -0.83 | -0.46 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.45 | -3.66 | -3.46 | -3.85 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 5.05 | 5.05 | 4.96 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.64 | -0.69 | -0.78 |
Diluted Net EPS (GAAP) | NA | -0.45 | -0.72 | -0.69 | -0.78 |